Trovagene raises $7m for precision cancer therapies

Trovagene (NSDQ:TROV) said today that it inked a deal with unnamed investors to sell approximately $7.1 million of its common stock. According to the deal, Trovagene plans to sell 6,191,500 shares of common stock. In a concurrent private placement, the biotech said it will issue warrants to buy up to 4,643,626 shares of common stock. Get the full story at our sister site, Drug Delivery Business News. The post Trovagene raises $7m for precision cancer therapies appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Diagnostics Funding Roundup Oncology Pharmaceuticals Wall Street Beat Trovagene Source Type: news

Related Links:

Electrochemical methods are powerful in the characterization and design of redox-modulating agents. We, herein, report the electrochemical investigation, in aprotic medium, of eleven synthetic 3-thio-substituted-nor-beta-lapachones, along with the determination of cytotoxic activity and correspondent selectivity index, against several cancer cell lines and one normal cell. Four of the quinones are novel compounds. The redox behavior is representative of two independent systems: the easy reduction of the quinone moiety and, at far more negative potential, the reductive cleavage of the C-S-C bonding; and the anodic part cont...
Source: Journal of the Brazilian Chemical Society - Category: Chemistry Source Type: research
(Natural News) In case you still weren’t sure about whether or not cancer is one of the worst things that can ever happen to anyone, you only need to look at what happens with most female cancer patients after they have undergone treatment. In the case of breast cancer patients, it’s possible to suffer from...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Condition:   Cutaneous Melanoma Interventions:   Behavioral: Demographics Questionnaire;   Behavioral: Adjuvant Treatment Beliefs Scale10;   Behavioral: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11;   Behavioral: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13;   Beh avioral: Decisional Regret14 Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
alho Carla Cruz M. Graça P. M. S. Neves The stabilization of G-Quadruplex DNA structures by ligands is a promising strategy for telomerase inhibition in cancer therapy since this enzyme is responsible for the unlimited proliferation of cancer cells. To assess the potential of a compound as a telomerase inhibitor, selectivity for quadruplex over duplex DNA is a fundamental attribute, as the drug must be able to recognize quadruplex DNA in the presence of a large amount of duplex DNA, in the cellular nucleus. By using different spectroscopic techniques, such as ultraviolet-visible, fluorescence and circular di...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
This study showed that potential vicious cycles underlying ARDs are quite diverse and unique, triggered by diverse and unique factors that do not usually progress with age, thus casting doubts on the possibility of discovering the single molecular cause of aging and developing the single anti-aging pill. Rather, each disease appears to require an individual approach. However, it still cannot be excluded that some or all of these cycles are triggered by fundamental processes of aging, such as chronic inflammation or accumulation of senescent cells. Nevertheless, experimental data showing clear cause and effect relationships...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, our findings indicate that GPR120 acts as a cancer-promoting receptor in the development of breast cancer. Therefore, GPR120 is expected to be a potential new target for cancer therapy.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
Abstract PURPOSE: To understand the meaning and impact for adult patients with cancer (past or present) of creating a digital story related to their cancer experience. PARTICIPANTS & SETTING: 10 participants made digital stories with the help of a research assistant trained in digital storytelling. This research took place in a large, urban center in Calgary, Alberta, Canada. METHODOLOGIC APPROACH: This research was done in the tradition of philosophical hermeneutics. Ten one-on-one interviews were conducted, and data were analyzed using an interpretive qualitative methodology. FINDINGS: Finding...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
n K. Iyer Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations, we report a new conjugate between the clinically approved PDL1 antibody (PDL1 AB) and drug Doxorubicin (Dox), named PDL1-Dox. We conjugated PDL1-Dox through a hydrazone linker containing a polyethylene glycol (PEG) spacer, which allows it to dissociate in a tumor environment and improves solubility. The purpose of using Dox is t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The U.S. Centers for Medicare&Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including an approved registry of patient results or clinical study to monitor patients for at least two years after treatment.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The U.S. Centers for Medicare&Medicaid Services (CMS) on Friday proposed Medicare coverage of approved CAR-T cell therapies that use the patient's immune system to fight cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Funding